BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kozbial K, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, Laferl H, Strasser M, Beinhardt S, Stättermayer AF, Gschwantler M, Zoller H, Maieron A, Graziadei I, Trauner M, Steindl-Munda P, Hofer H, Ferenci P. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. Liver Int 2018;38:1028-35. [PMID: 29136329 DOI: 10.1111/liv.13629] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Negro F. Residual risk of liver disease after hepatitis C virus eradication. J Hepatol 2021;74:952-63. [PMID: 33276027 DOI: 10.1016/j.jhep.2020.11.040] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Lawitz E, Poordad F, Gutierrez JA, Beumont M, Beets G, Vandevoorde A, Remoortere PV, Luo D, Vijgen L, Eygen VV, Gamil M. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health Sci Rep 2020;3:e145. [PMID: 32270053 DOI: 10.1002/hsr2.145] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Isfordink CJ, Maan R, de Man RA, van Erpecum KJ, van der Meer AJ. Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection? Eur J Intern Med 2021:S0953-6205(21)00296-X. [PMID: 34563447 DOI: 10.1016/j.ejim.2021.08.023] [Reference Citation Analysis]
4 Ciancio A, Ribaldone DG, Dotta A, Giordanino C, Sacco M, Fagoonee S, Pellicano R, Saracco GM. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents. Liver Int 2021;41:276-87. [PMID: 32998174 DOI: 10.1111/liv.14676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Faillaci F, Marzi L, Critelli R, Milosa F, Schepis F, Turola E, Andreani S, Vandelli G, Bernabucci V, Lei B, D'Ambrosio F, Bristot L, Cavalletto L, Chemello L, Sighinolfi P, Manni P, Maiorana A, Caporali C, Bianchini M, Marsico M, Turco L, de Maria N, Del Buono M, Todesca P, di Lena L, Romagnoli D, Magistri P, di Benedetto F, Bruno S, Taliani G, Giannelli G, Martinez-Chantar ML, Villa E. Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals. Hepatology. 2018;68:1010-1024. [PMID: 29604220 DOI: 10.1002/hep.29911] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 21.0] [Reference Citation Analysis]
6 Peleg N, Issachar A, Sneh Arbib O, Cohen‐naftaly M, Harif Y, Oxtrud E, Braun M, Leshno M, Barsheshet A, Shlomai A. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response. J Viral Hepat 2019;26:1257-65. [DOI: 10.1111/jvh.13167] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
7 Laursen TL, Siggaard CB, Kazankov K, Sandahl TD, Møller HJ, Tarp B, Kristensen LH, Laursen AL, Leutscher P, Grønbæk H. Time‐dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct‐acting antiviral therapy of chronic hepatitis C. J Viral Hepat 2019;27:28-35. [DOI: 10.1111/jvh.13204] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
8 Pons M, Rodríguez-Tajes S, Esteban JI, Mariño Z, Vargas V, Lens S, Buti M, Augustin S, Forns X, Mínguez B, Genescà J. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J Hepatol 2020;72:472-80. [PMID: 31629779 DOI: 10.1016/j.jhep.2019.10.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 16.7] [Reference Citation Analysis]
9 Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018;69:1178-1187. [PMID: 30006068 DOI: 10.1016/j.jhep.2018.07.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 14.5] [Reference Citation Analysis]
10 Kozbial K, Al‐zoairy R, Gschwantler M, Stauber R, Hametner S, Laferl H, Strasser M, Hayat‐khayyati A, Datz C, Kramer L, Schaefer B, Maieron A, Graziadei I, Stättermayer AF, Beinhardt S, Munda P, Zoller H, Holzmann H, Aberle SW, Trauner M, Hofer H, Ferenci P. Management of patients with chronic hepatitis C failing repeated courses of interferon‐free direct acting antiviral combination therapy. GastroHep 2019;1:76-83. [DOI: 10.1002/ygh2.329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
11 Negro F. Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy. Cold Spring Harb Perspect Med 2020;10:a036921. [PMID: 31636094 DOI: 10.1101/cshperspect.a036921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Nabatchikova EA, Abdurakhmanov DT, Rozina TP, Nikulkina EN, Tanaschuk EL, Moiseev SV. Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience. Clin Res Hepatol Gastroenterol 2021;:101714. [PMID: 33930587 DOI: 10.1016/j.clinre.2021.101714] [Reference Citation Analysis]
13 Laursen TL, Sandahl TD, Kazankov K, Eriksen PL, Kristensen LH, Holmboe CH, Laursen AL, Vilstrup H, Grønbæk H. Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis. Am J Physiol Gastrointest Liver Physiol 2020;319:G151-6. [PMID: 32597708 DOI: 10.1152/ajpgi.00128.2020] [Reference Citation Analysis]
14 Kim NJ, Magee C, Cummings C, Park H, Khalili M. Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population. Hepatol Commun 2018;2:1274-83. [PMID: 30288480 DOI: 10.1002/hep4.1246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
15 Schein CH. Repurposing approved drugs on the pathway to novel therapies. Med Res Rev 2020;40:586-605. [PMID: 31432544 DOI: 10.1002/med.21627] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
16 Ma L, Liu J, Wang W, Yang F, Li P, Cai S, Zhou X, Chen X, Zhuang X, Zhang H, Cao G. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. Future Oncol. 2020;16:675-686. [PMID: 32223423 DOI: 10.2217/fon-2019-0845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Cerrito L, Ainora ME, Nicoletti A, Garcovich M, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. World J Hepatol 2021; 13(11): 1663-1676 [PMID: 34904036 DOI: 10.4254/wjh.v13.i11.1663] [Reference Citation Analysis]
18 Pereira Guedes T, Fragoso P, Lemos C, Garrido M, Silva J, Falcão D, Maia L, Moreira T, Manuel Ferreira J, Pedroto I. Long-Term Follow-Up of Advanced Liver Disease after Sustained Virological Response to Treatment of Hepatitis C with Direct-Acting Antivirals: Outcomes from a Real-World Portuguese Cohort. GE Port J Gastroenterol 2020;27:149-59. [PMID: 32509920 DOI: 10.1159/000503074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Butt N, Anoshia, Khan MA, Akbar A. Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi. Pak J Med Sci 2021;37:2014-9. [PMID: 34912436 DOI: 10.12669/pjms.37.7.4627] [Reference Citation Analysis]
20 Nabatchikova EA, Abdurakhmanov DT, Nikulkina EN, Rozina TP, Tanaschuk EL, Nikiforova NV, Adonyeva VS, Moiseev SV. [The long-term prospective study of patients with liver cirrhosis after elimination of the hepatitis C virus]. Ter Arkh 2020;92:34-42. [PMID: 32598716 DOI: 10.26442/00403660.2020.02.000511] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci. 2020;17:892-902. [PMID: 32308542 DOI: 10.7150/ijms.43079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
22 Huang P, Wang Y, Yue M, Ge Z, Xia X, Jeyarajan AJ, Holmes JA, Yu R, Zhu C, Yang S, Lin W, Chung RT. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver Int 2021. [PMID: 34051040 DOI: 10.1111/liv.14976] [Reference Citation Analysis]
23 Janczewska E, Zarębska-Michaluk D, Berak H, Piekarska A, Gietka A, Dybowska D, Mazur W, Belica-Wdowik T, Dobracki W, Tudrujek-Zdunek M, Deroń Z, Buczyńska I, Sitko M, Czauż-Andrzejuk A, Lorenc B, Białkowska-Warzecha J, Citko J, Laurans Ł, Jaroszewicz J, Socha Ł, Tronina O, Adamek B, Horban A, Halota W, Baka-Ćwierz B, Tomasiewicz K, Simon K, Garlicki A, Wawrzynowicz-Syczewska M, Flisiak R. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. BMC Infect Dis 2018;18:580. [PMID: 30445916 DOI: 10.1186/s12879-018-3465-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Kawaguchi I, Chayama K, Gonzalez YS, Virabhak S, Mitchell D, Yuen C, Kumada H. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. Adv Ther 2020;37:457-76. [PMID: 31808054 DOI: 10.1007/s12325-019-01166-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
25 Guardigni V, Cento V, Ianniruberto S, Badia L, Aragri M, Conti M, Perno CF, Viale P, Ceccherini-Silberstein F, Verucchi G. HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals. Infection 2018;46:717-20. [PMID: 29804205 DOI: 10.1007/s15010-018-1158-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Flisiak R, Janczewska E, Łucejko M, Karpińska E, Zarębska-Michaluk D, Nazzal K, Bolewska B, Białkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Simon K, Piekarska A, Tronina O, Tuchendler E, Garlicki A. Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. J Viral Hepat 2018;25:1298-305. [PMID: 29888828 DOI: 10.1111/jvh.12945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
27 Galati G, Muley M, Viganò M, Iavarone M, Vitale A, Dell'Unto C, Lai Q, Cabibbo G, Sacco R, Villa E, Trevisani F. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. Expert Opin Drug Saf 2019;18:603-10. [PMID: 31067134 DOI: 10.1080/14740338.2019.1617272] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
28 Flisiak R, Zarębska-Michaluk D, Janczewska E, Łapiński T, Rogalska M, Karpińska E, Mikuła T, Bolewska B, Białkowska J, Flejscher-Stępniewska K, Tomasiewicz K, Karwowska K, Pazgan-Simon M, Piekarska A, Berak H, Tronina O, Garlicki A, Jaroszewicz J. Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy. Cancers (Basel) 2021;13:3694. [PMID: 34359594 DOI: 10.3390/cancers13153694] [Reference Citation Analysis]
29 Laursen TL, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol 2020; 26(22): 2931-2947 [PMID: 32587440 DOI: 10.3748/wjg.v26.i22.2931] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F, Zentilin P, Savarino V. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. Eur J Clin Invest. 2019;49:e13056. [PMID: 30474209 DOI: 10.1111/eci.13056] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
31 Reig M, Cabibbo G. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). J Hepatol 2021;74:1225-33. [PMID: 33582128 DOI: 10.1016/j.jhep.2021.01.046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
32 Ribaldone DG, Sacco M, Saracco GM. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. J Clin Med. 2020;9. [PMID: 32092892 DOI: 10.3390/jcm9020563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
33 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
34 Wang ZR, Chen H, Gao SS, Qiu H, Li HW, Sun ZL, Wang JM. Implications of soluble E-cadherin level of antiviral treatment in patients with chronic hepatitis C virus infection. Int Immunopharmacol 2019;74:105708. [PMID: 31254956 DOI: 10.1016/j.intimp.2019.105708] [Reference Citation Analysis]
35 Strauss E. CHRONIC HEPATITIS C IS STILL A PROBLEM FOR THE PUBLIC HEALTH CARE SYSTEM IN BRAZIL. Arq Gastroenterol 2018;55:321-3. [PMID: 30785512 DOI: 10.1590/S0004-2803.201800000-90] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Corma-gómez A, Macías J, Téllez F, Freyre-carrillo C, Morano L, Rivero-juárez A, Ríos MJ, Alados JC, Vera-méndez FJ, Merchante N, Palacios R, Granados R, Merino D, De Los Santos I, Pineda JA. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. Clinical Infectious Diseases 2019. [DOI: 10.1093/cid/ciz1140] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
37 Vitrone M, Parrella A, Albisinni R, Durante-Mangoni E, Zampino R. Dynamics and management of oral anticoagulant treatment in chronic hepatitis C patients undergoing therapy with direct antiviral agents. J Chemother 2019;31:86-9. [PMID: 30784359 DOI: 10.1080/1120009X.2019.1571661] [Reference Citation Analysis]